THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY

Marat Fudim,Renato D. Lopes,John H. Alexander,Daniel Wojdyla,Justin Ezekowitz,Michael Hanna,Dan Atar,Ziad Hijazi,Maria Cecilia Bahit,J Lopez-Sendon,Lars Wallentin,Christopher B. Granger,Stefan H. Hohnloser

THE EFFICACY AND SAFETY OF APIXABAN VERSUS WARFARIN ARE PRESERVED IN PATIENTS WITH ATRIAL FIBRILLATION AND EXTREMELY HIGH BODY WEIGHT: INSIGHTS FROM THE ARISTOTLE STUDY

2018

Marat Fudim
Renato D. Lopes
John H. Alexander
Daniel Wojdyla
Justin Ezekowitz
Michael Hanna
Dan Atar
Ziad Hijazi
Maria Cecilia Bahit
J Lopez-Sendon
Lars Wallentin
Christopher B. Granger
Stefan H. Hohnloser

Recent guidelines caution against the use of non-vitamin K antagonists oral anticoagulants (NOACs) in patients with extremely high body weight (≥120 kg) due to lack of data in this population. We evaluated the efficacy and safety of apixaban versus warfarin in heavy patients with atrial

Keywords:

Population
Atrial fibrillation
Cardiology
Diabetes mellitus
Apixaban
Warfarin
Internal medicine
Body weight
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations